Finnrick - Ensuring a Safer and More Transparent Supply Chain
Xingruida XDR

Xingruida XDR

Tirzepatide

Finnrick tested 5 samples of Tirzepatide (GLP-1 and GIP agonist) from Xingruida XDR between 4 Sep 2025 and 17 Oct 2025. Test scores average over 5, no score below 4, and at least 2 tests warrant a tentative Finnrick Rating of C (Okay).

Finnrick Rating™
C
OKAY
Tentative Rating
Xingruida XDR
Tirzepatide
Tested 5 Samples
Last test 17 Oct 2025

Take Action

Researcher

Request Full Data Access to the Finnrick database of peptide tests.

Free peptide testing

Mail in a sample (US only) to get confidence for the specific vials you have, and contribute to identifying unsafe supply chains, so other people can avoid risky and costly mistakes.

Other Tirzepatide tests from top-rated vendors:

All Tirzepatide tests from Xingruida XDR

Samples are tested in commercial labs

Tests Count

5

Scores

AVG7.3MIN4.3MAX10.0

Last

17 Oct 2025

First

4 Sep 2025
Quantity
Test DateCertificate
Test Score
LabelTestedDifferencePurityBatch IDContainerTested AtSent By
17 Oct 2025View7.960mg63.100mg+5.2%99.95%(no batch ID)No Label / Silver Crimp / Orange Cap Lab EPublic
14 Oct 2025View6.560mg72.900mg+21.5%99.70%Jul 15, 2025White Label / Silver Crimp / Orange Cap Lab GPublic
1 Oct 2025View4.340mg53.900mg+34.8%99.70%(no batch ID)(no data)Lab GPublic
4 Sep 2025View8.020mg19.100mg-4.5%99.95%(no batch ID)Purple Label / Silver Crimp / Purple CapLab EPublic
4 Sep 2025View10.030mg30.100mg+0.3%99.95%July 2 2025 White Label / Silver Crimp / Pink Cap Lab EPublic